Journal of Antimicrobial Chemotherapy (1999) 43, 37-45
© 1999 The British Society for Antimicrobial Chemotherapy
An in-vitro study of the antimicrobial susceptibilities of Yersinia enterocolitica and the definition of a database
Pharmazeutische Mikrobiologie, University of Bonn, Meckenheimer Allee 168, D-53115, Bonn, Germany
The antibiotic susceptibilities of 151 Yersinia enterocolitica strains isolated from humans, animals and the environment, and belonging to biovars 1A (n = 22), 1B (n = 13), 2 (n = 12), 3 (n = 31), 4 (n = 63) and 5 (n = 10) to 71 antibiotics were examined. Biovars could be characterized phenotypically by their similar antibiograms. For the majority of biovars only minor differences in susceptibilities were detected. Ninety-nine percent of all Yersinia strains were resistant to amoxycillin, but biovar-related differences in MICs were demonstrated. Significant differences, characteristic of specific biovars, were detected for fosfomycin, some ß-lactams (in particular amoxycillin/clavulanate, and ticarcillin). Strains of biovar 1A were resistant or of intermediate susceptibility to ticarcillin and had fosfomycin MICs of 16–64 mg/L and amoxycillin/ clavulanate MICs of 4–32 mg/L. Most strains of biovar 1B (n = 11) were sensitive to amoxycillin/clavulanate (MIC = 0.5–2 mg/L). Most strains of biovar 2 (n = 10) showed an antibiotic phenotype resembling that of strains of biovar 1A, but they were more susceptible to fosfomycin (MIC = 4–16 mg/L). Twenty-seven strains of biovar 3 had amoxycillin/clavulanate MICs of 4–32 mg/L; 19 of them were sensitive to ticarcillin and fosfomycin. Biovar 4 strains were uniformly sensitive or of intermediate susceptibility to amoxycillin/clavulanate (MIC = 0.5–4 mg/L), sensitive to fosfomycin (MIC = 1–4 mg/L) but resistant to ticarcillin. The prevailing antibiotic phenotype of biovar 5 (n = 7) was similiar to the phenotype of biovar 4, although these biovar 5 strains were slightly more susceptible to amoxycillin/clavulanate and showed a heterogeneous pattern of susceptibility to fosfomycin (MIC = 1–32 mg/L). The results of this study show that unambiguous statements cannot be made about the natural antibiotic susceptibility to certain ß-lactams and fosfomycin of Y. enterocolitica. The data indicate a complex regulation of ß-lactamases in Y. enterocolitica. Some ß-lactamases are found more frequently or will be expressed predominantly in specific biovars.
* Corresponding author. Tel:+49-229-735272; Fax:+49-228-735267.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. P. Falcao, D. P. Falcao, A. Pitondo-Silva, A. C. Malaspina, and M. Brocchi Molecular typing and virulence markers of Yersinia enterocolitica strains from human, animal and food origins isolated between 1968 and 2000 in Brazil. J. Med. Microbiol., November 1, 2006; 55(Pt 11): 1539 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. STOCK, B. HENRICHFREISE, and B. WIEDEMANN Natural antibiotic susceptibility and biochemical profiles of Yersinia enterocolitica-like strains: Y. bercovieri, Y. mollaretii, Y. aldovae and 'Y. ruckeri' J. Med. Microbiol., January 1, 2002; 51(1): 56 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Stock and B. Wiedemann Natural antimicrobial susceptibilities of Plesiomonas shigelloides strains J. Antimicrob. Chemother., December 1, 2001; 48(6): 803 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Williams Jr Fluoroquinolones for Respiratory Infections : Too Valuable To Overuse Chest, December 1, 2001; 120(6): 1771 - 1775. [Full Text] [PDF]
|
|
|
|
|
|
I. STOCK and B. WIEDEMANN Natural antibiotic susceptibility of Klebsiella pneumoniae, K. oxytoca, K. planticola, K. ornithinolytica and K. terrigena strains J. Med. Microbiol., May 1, 2001; 50(5): 396 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Pham, S. M. Bell, L. Martin, and E. Carniel The {beta}-lactamases and {beta}-lactam antibiotic susceptibility of Yersinia enterocolitica J. Antimicrob. Chemother., December 1, 2000; 46(6): 951 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fernandez-Roblas, F. Cabria, J. Esteban, J. C. Lopez, I. Gadea, and F. Soriano In vitro activity of gemifloxacin (SB-265805) compared with 14 other antimicrobials against intestinal pathogens J. Antimicrob. Chemother., December 1, 2000; 46(6): 1023 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Prats, B. Mirelis, T. Llovet, C. Muñoz, E. Miró, and F. Navarro Antibiotic Resistance Trends in Enteropathogenic Bacteria Isolated in 1985-1987 and 1995-1998 in Barcelona Antimicrob. Agents Chemother., May 1, 2000; 44(5): 1140 - 1145. [Abstract] [Full Text]
|
|
|
|
|
|
I. STOCK, P. HEISIG, and B. WIEDEMANN {beta}-Lactamase expression in Yersinia enterocolitica biovars 1A, 1B and 3 J. Med. Microbiol., May 1, 2000; 49(5): 403 - 408. [Abstract] [Full Text] [PDF]
|
|